GTS Securities’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
GTS Securities's IBRX Position: Q3 2026 in Review
GTS Securities sold out of ImmunityBio (IBRX) in Q3 2026, closing a stake of 13,465 shares — an estimated $118K sold.
GTS Securities first reported a position in IBRX in Q1 2024 and held it in 3 quarters. The position peaked at $118K in Q2 2026. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- GTS Securities reported no remaining ImmunityBio position as of Q3 2026 after selling out during the quarter.
- GTS Securities sold 13,465 ImmunityBio shares in Q3 2026, an estimated $118K.
- GTS Securities first reported a position in ImmunityBio in Q1 2024 and held it in 3 quarters.
- GTS Securities's ImmunityBio position peaked at $118K in Q2 2026.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on GTS Securities's 13F filing for Q3 2026, filed 16 Nov 2026.